<DOC>
	<DOCNO>NCT02469883</DOCNO>
	<brief_summary>This study conduct assess maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) , evaluate pharmacokinetics , safety preliminary anti-tumor activity Sinotecean .</brief_summary>
	<brief_title>A Study Sinotecean Tolerance Pharmacokinetics</brief_title>
	<detailed_description />
	<criteria>late malignant tumor patient diagnose pathological and/or cytological ; lack standard treatment treatment failure ; 1865years , ECOG:01 , expect survival period &gt; 3 month ; main organ function normal ; sign date informed consent participate clinical trial four week ; currently effective treatment ; end antitumor treatment within 4 week ( end Nitrosourea/Mitomycin within 6 week ) ; AE â‰¥ Grade 2 ( accord NCICTC 4.0 ) , except hair loss ; ischemic heart disease , heart failure , severe arrhythmia , cerebrovascular disease , asthma , severe infection , active peptic ulcer ; urine protein : ++ , urinary 24 hour &gt; 1.0g ; uncontrolled primary metastatic brain ; immunodeficiency history ; accord researcher 's judgment , concomitant diseases seriously endanger patient obstruct patient complete clinical trial ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>